NL
ARQT icon

NVWM LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

NVWM LLC’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.6K Hold
1,000
– – 0.01% 270
2025
Q4 		$29K Hold
1,000
– – 0.01% 262
2025
Q3 		$18.9K Buy
+1,000
New +$15.8K ﹤0.01% 293

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NVWM LLC's ARQT Position: Q1 2026 in Review

NVWM LLC held its Arcutis Biotherapeutics (ARQT) position steady in Q1 2026 at 1,000 shares worth $23.6K. The position accounts for 0.01% of the portfolio, ranked #270.

NVWM LLC first reported a position in ARQT in Q3 2025 and has held it in 3 quarters since. The position peaked at $29K in Q4 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • NVWM LLC held 1,000 shares of Arcutis Biotherapeutics worth $23.6K as of Q1 2026.
  • NVWM LLC left its Arcutis Biotherapeutics share count unchanged in Q1 2026.
  • Arcutis Biotherapeutics made up 0.01% of NVWM LLC's portfolio in Q1 2026, its #270 holding.
  • NVWM LLC first reported a position in Arcutis Biotherapeutics in Q3 2025 and has held it in 3 quarters since.
  • NVWM LLC's Arcutis Biotherapeutics position peaked at $29K in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on NVWM LLC's 13F filing for Q1 2026, filed 27 Apr 2026.